77 related articles for article (PubMed ID: 29095060)
21. Multiplex fusion gene testing in pediatric acute myeloid leukemia.
Iijima-Yamashita Y; Matsuo H; Yamada M; Deguchi T; Kiyokawa N; Shimada A; Tawa A; Takahashi H; Tomizawa D; Taga T; Kinoshita A; Adachi S; Horibe K
Pediatr Int; 2018 Jan; 60(1):47-51. PubMed ID: 29105243
[TBL] [Abstract][Full Text] [Related]
22. Predictors for requiring re-induction chemotherapy in acute myeloid leukemia patients with residual disease on day 14 bone marrow assessment.
Nachar VR; Perissinotti AJ; Scappaticci GB; Bixby DL; Marini BL
Leuk Res; 2017 Dec; 63():56-61. PubMed ID: 29102597
[TBL] [Abstract][Full Text] [Related]
23. Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects.
Eriksson A; Chantzi E; Fryknäs M; Gullbo J; Nygren P; Gustafsson M; Höglund M; Larsson R
Leuk Res; 2017 Dec; 63():41-46. PubMed ID: 29100024
[TBL] [Abstract][Full Text] [Related]
24. Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia.
Dumas PY; Bertoli S; Bérard E; Médiavilla C; Yon E; Tavitian S; Leguay T; Huguet F; Forcade E; Milpied N; Sarry A; Sauvezie M; Bories P; Pigneux A; Récher C
Oncotarget; 2017 Oct; 8(45):79126-79136. PubMed ID: 29108292
[TBL] [Abstract][Full Text] [Related]
25. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
26. Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors.
Assi R; Kantarjian H; Ravandi F; Daver N
Curr Opin Hematol; 2018 Mar; 25(2):136-145. PubMed ID: 29206680
[TBL] [Abstract][Full Text] [Related]
27. Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia.
Li F; Sutherland MK; Yu C; Walter RB; Westendorf L; Valliere-Douglass J; Pan L; Cronkite A; Sussman D; Klussman K; Ulrich M; Anderson ME; Stone IJ; Zeng W; Jonas M; Lewis TS; Goswami M; Wang SA; Senter PD; Law CL; Feldman EJ; Benjamin DR
Mol Cancer Ther; 2018 Feb; 17(2):554-564. PubMed ID: 29142066
[TBL] [Abstract][Full Text] [Related]
28. Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance:
Li J; Kumar P; Anreddy N; Zhang YK; Wang YJ; Chen Y; Talele TT; Gupta K; Trombetta LD; Chen ZS
Oncotarget; 2017 Nov; 8(55):93785-93799. PubMed ID: 29212189
[TBL] [Abstract][Full Text] [Related]
29. Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy.
Taylor SJ; Langdon WY
Mol Cell Oncol; 2017; 4(6):e1378156. PubMed ID: 29209657
[TBL] [Abstract][Full Text] [Related]
30. [Analysis of prognosis of acute myeloid leukemia patients based on genetic mutations].
Shi J; Zhu Y; Hong M; Zhao H; Mao J; Jin H; Zhang W; Zhang T; Ma Y; Chen Y; Qian S; Li J; Qiao C
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2017 Dec; 34(6):806-811. PubMed ID: 29188605
[TBL] [Abstract][Full Text] [Related]
31. DOCK2: A novel FLT3/ITD leukemia drug target.
Wu M; Small D; Duffield AS
Oncotarget; 2017 Oct; 8(51):88253-88254. PubMed ID: 29179430
[No Abstract] [Full Text] [Related]
32. Tasigna (nilotinib) in chronic myeloid leukemia treatment-free remission after nearly 2 years: an interview with Adam Mead.
Mead A
Future Oncol; 2017 Nov; 13(27):2401-2404. PubMed ID: 29124948
[TBL] [Abstract][Full Text] [Related]
33. Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes.
Wang H; Li Y; Lv N; Li Y; Wang L; Yu L
Ann Hematol; 2018 Nov; 97(11):2025-2038. PubMed ID: 30084010
[TBL] [Abstract][Full Text] [Related]
34. AML: Predicting the Unpredictable.
Takahashi K
Cell Stem Cell; 2018 Aug; 23(2):162-163. PubMed ID: 30075128
[TBL] [Abstract][Full Text] [Related]
35. Predictive and Prognostic Markers in Adults With Acute Myeloid Leukemia: A Single-Institution Experience.
Gbadamosi B; Ezekwudo D; Bastola S; Jaiyesimi I
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):e287-e294. PubMed ID: 29803615
[TBL] [Abstract][Full Text] [Related]
36. The Prognostic Value of TP53 Mutations in Adult Acute Myeloid Leukemia: A Meta-Analysis.
Qin G; Han X
Transfus Med Hemother; 2023 Jun; 50(3):234-244. PubMed ID: 37435002
[TBL] [Abstract][Full Text] [Related]
37. Genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways mediating sorafenib resistance in acute myeloid leukemia.
Damnernsawad A; Bottomly D; Kurtz SE; Eide CA; McWeeney SK; Tyner JW; Nechiporuk T
Haematologica; 2022 Jan; 107(1):77-85. PubMed ID: 33375770
[TBL] [Abstract][Full Text] [Related]
38. Clinical efficacy of decitabine in combination with standard-dose cytarabine, aclarubicin hydrochloride, and granulocyte colony-stimulating factor in the treatment of young patients with newly diagnosed acute myeloid leukemia.
Dou L; Xu Q; Wang M; Xiao Y; Cheng L; Li H; Huang W; Mei J; Jing Y; Bo J; Liu D; Yu L
Onco Targets Ther; 2019; 12():5013-5023. PubMed ID: 31303761
[No Abstract] [Full Text] [Related]
39. Chronic myelomonocytic leukemia associated with myeloid sarcomas and
Matanes F; AbdelAzeem BMA; Shah G; Reddy V; Saad A; Papadantonakis N
Ther Adv Hematol; 2019; 10():2040620719854596. PubMed ID: 31217941
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 Relationship.
Liu T; Ivaturi V; Sabato P; Gobburu JVS; Greer JM; Wright JJ; Smith BD; Pratz KW; Rudek MA;
Clin Transl Sci; 2018 Jul; 11(4):435-443. PubMed ID: 29702736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
